Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Masanori AtsukawaAkihito TsubotaChisa KondoHidenori ToyodaMakoto NakamutaKoichi TakaguchiTsunamasa WatanabeAtsushi HiraokaHaruki UojimaToru IshikawaMotoh IwasaToshifumi TadaAkito NozakiMakoto ChumaShinya FukunishiToru AsanoChikara OgawaHiroshi AbeKeizo KatoNaoki HottaToshihide ShimaKentaro MatsuuraShigeru MikamiYoshihiko TachiShinichi FujiokaHironao OkuboNoritomo ShimadaJoji TaniAkihiro MorishitaIsao HidakaAkio MoriyaKunihiko TsujiTakehiro AkahaneTomomi OkuboTaeang AraiMichika KitamuraKiyoshi MoritaKazuhito KawataYasuhito TanakaTakashi KumadaKatsuhiko Iwakirinull nullPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)
Achievement of SVR with sofosbuvir/velpatasvir improved the liver functional reserve at 12 weeks post-treatment and maintained the stable effects until 48 weeks post-treatment in patients with decompensated cirrhosis. Specifically, the patients with less advanced conditions had the likelihood of improving to Child-Pugh class A at 48 weeks post-treatment. This article is protected by copyright. All rights reserved.